Powering breakthroughs
and paradigm shifts.
UK | USA | UAE
Our Focus
Defence- Securing Tomorrow's Strategic Advantage Today
We invest in technologies that redefine national resilience and asymmetric advantage. From battlefield autonomy to cyber-physical infrastructure, we focus on dual-use platforms, command systems, advanced ISR (intelligence, surveillance, reconnaissance), and supply-chain independence in a world where state capability is being redefined by innovative technologies.
The next decade will witness a 3-5x increase in defence-tech dual-use applications, driven by sovereign demand and AI-augmented capabilities.
We back companies that can secure early procurement traction while maintaining commercial scale potential — across aerospace, critical systems, and secure compute.
The future of defence goes far beyond government labs, Specialised, well governed ventures now stand to change the game!
Get in touch
ENERGY, Investing in the Fundamental of Power Transition
Our energy thesis is centred on the alternates and the enablers — whether grid-flexibility infrastructure intelligence, industrialial bio-fuels, or novel energy storage and materials. We invest in businesses with capital efficiency, regulatory headroom, and irreversible demand curves driven by policy and pricing mechanisms.
Over $5T in capital will be deployed globally by 2030 into new energy and carbon counters. The winners will enable new baselines in power, storage, and material science.
We pursue early bets on companies that sit between legacy infra and net-zero mandates — from second-life batteries to high-density micro-grids.
The future of energy goes far beyond generation — storage and optimsation stand to excel.
Get in touch
Health , Rewiring the Biology of Care
We focus on technologies that compress the time between insight and intervention — spanning AI-native diagnostics, decentralised clinical tools, and bioinformatics platforms that translate data into outcomes. Our portfolio targets companies solving for cost, accessibility, and speed — at both molecular and systems level.
Healthcare is shifting from reactive treatment to precision platforms; AI-native companies will lead the compression of diagnostic timelines by 70%+ in the next 5 years.
We focus on regulatory-savvy founders solving cross-border health bottlenecks — especially those commercialising across Asia, MENA, and high-growth global corridors.
Tomorrow’s healthcare winners will lead via proactive care, discovery and multifaceted data care.
Get in touch
At Clover Lance, we fuel the bold and partner with the transformative.
